Cellectis and AstraZeneca in US$2.2bn dealAstraZeneca plc has paid French cancer cell therapy developer Cellectis SA US$25m upfront and US$220m in equity in an US$2.2bn R&D deal for up to ten cell and gene therapies. more ➔
Alfasigma SpA set to take over Galapagos...Italian pharma company Alfasigma SpA has signed a letter of intent to acquire the filgotinib business from Galapagos. more ➔
Abingworth raises $356m for new CCD fundRaising $356m through a new Clinical Co-Development Co-Investment Fund (CCD-CIF), Carlyle-subsidiary Abingworth has extended its capital base for late-stage clinical bio-pharma programmes. more ➔
TCMStudy links TCM with effects on protein...By mapping out associations between human protein networks and herbs used in traditional Chinese medicine (TCM), a Chinese-Bulgarian team can predict relief on various disease symptoms. more ➔
Cancer vaccinesBioNtech reports Car-T/mRNA booster stud...BioNtech SE has reported preliminary Phase I/II results with BNT211-01 (NEO-PTC-01) and CarVAC at ESMO conference in Madrid more ➔
M&ARoche acquires Telavant Holdings to win...Analysts describe as sporting the €7.1bn for Roche AG’s acquisition of Roivant subsidiary Telavant Holdings. more ➔
AMRUK boosts AMR defenses with £30m PACE in...In an effort to address the global health threat of antimicrobial resistance (AMR), Innovate UK, LifeArc, and Medicines Discovery Catapult have jointly launched the PACE (Pathways to Antimicrobial Clinical … more ➔
CPHI: Trends shaping pharma’s pathThis week CPHI 2023 will unite industry leaders, innovators, and start-ups to explore sustainable solutions, cutting-edge technologies, and collaborative partnerships. more ➔
FinancingXlife Sciences AG acquires 20% stake in...In a significant financial milestone, Xlife Sciences AG invests CHF23.3m in 4D Lifetec AG. With the agreement signed today, Xlife Sciences is not only bringing in a direct cash investment, but also an … more ➔
CollaborationSpliceBio has made up a US $216m allianc...SpliceBio has licenced its intein technlogy to Roche’s gene therapy subsidiary Spark Therapeutics to develop a gene therapy targeting an undisclosed inherited retinal disease. more ➔
